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Abstract The human leukocyte chemoattractant receptors for 
complement factor C5a (C5a-R) and N-formylated peptides 
(fMLF-R) are important members of the supeffamily of G-pro- 
tein coupled receptors (GPCR). Uniquely among the GPCR, 
these two receptors cannot be expressed in a functionally active 
form in the oocytes of the frog Xenopus laevis, but require substi- 
tution of total RNA of the myelomonocytic U-937 or HL-60 cell 
lines, respectively. Recently, it was reported that the C5a-R may 
couple to the ~ subunit of G-16. We have tested this G-protein 
for its ability to complement the signal transduction cascade of 
the C5a-R and fMLF-R in Xenopus oocytes. Injection of cRNA 
for the C5a-R in combination with G~-I6 led to expression of a 
functional CSa-R as measured by ligand-induced whole cell cur- 
rent. In contrast o a previous report, the fMLF-R exhibited some 
residual functional activity when transiently expressed in Xen- 
opus oocytes the extent of which could, however, substantially be 
increased by coexpression of Ga-16. Thus, Ga-16 complements 
the signal transduction cascade of both receptors in Xenopus 
laevis oocytes and is most likely the complementing factor present 
in the U-937 and HL-60 cell lines. 
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1. Introduction 
The complement factor C5a (C5a) and N-formylmethionyl 
peptides (fMLF) are important mediators of inflammatory 
reactions acting via two different receptors, the human C5a 
receptor (C5a-R) and tMLF receptor (fMLF-R). C5a is gener- 
ated during activation of the complement cascade, N- 
formylated peptides are believed to derive from degraded bac- 
terial proteins [1] or to be generated from mitochondrial pro- 
teins upon tissue damage [2]. Both substances are able to trigger 
the direct locomotion of neutrophils to the sites of bacterial 
infection and to stimulate a variety of biochemical nd cellular 
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responses, like induction of the oxidative burst and release of 
intracellular enzymes (for review see [3,4]). 
The human fMLF-R and C5a-R have both been cloned [5-7]. 
They belong to the family of G-protein coupled receptors 
(GPCR) which are characterized by a common motif of seven 
transmembrane s-helices connected by hydrophilic extra- and 
intracellular loops, and a signal transduction pathway involv- 
ing heterotrimeric G-proteins. Much effort has been devoted 
to the study of the structural and functional characteristics of 
these receptor-ligand pairs as a prerequisite for the develop- 
ment of rational intervention strategies. 
Oocytes of the frog Xenopus laevis are commonly used to 
express GPCR in a functionally active form. This expression 
system has been successfully used to clone and characterize 
several GPCR, like the receptors for serotonin [8] and platelet- 
activating factor [9], and to characterize receptor mutants 
[10,11]. Several groups, including ourselves, have employed this 
system in an attempt to establish a functional expression system 
for the human fMLF-R and C5a-R. Uniquely among the 
GPCR tested so far, it was found that these two receptors 
require a complementing factor present in the RNA of myelo- 
monocytic cell lines, like HL-60 and U-937, for functional ctiv- 
ity [12 15]. Recently, it was reported that a G-protein ~ sub- 
unit, G~-16, may selectively couple to the human C5a-R in 293 
and COS cell lines [16,17]. Here, we report that Ga-16, a G- 
protein that is expressed in HL-60 and U-937 cell lines, is able 
to restore the signal transduction cascade of the C5a-R and 
fMLF-R in Xenopus oocytes and therefore most probably rep- 
resents the complementing factor previously described in these 
cell lines. 
2. Materials and methods 
2.1. Materials 
The U-937 cell line was obtained from ATCC. The fMLF-R cDNA 
in plasmid vector pCDM8 (Invitrogen) coding for the fMLF-R98 var- 
iant [5] was donated by F. Boulay (Grenoble, France). The coding 
sequence for G0~-16 in vector pCMV5 was kindly given by G.L. 
Johnson (Denver, USA). Construction ofpCC1 containing the C5a-R 
coding sequence inplasmid pCDM8 was reported earlier [14]. Recom- 
binant human C5a was purified from our own recombinant E. coli 
strain as described elsewhere [18]. Adult Xenopus laevis frogs were 
purchased from Nasco (Alabama, USA). Composition of ND96:96 
mM NaCI, 2 mM KC1, 1.8 mM CaC12, 1 mM MgCIz, 5 mM HEPES, 
pH 7.4. Bovine serum albumin (0.2% (w/v); Boehringer) was added to 
ND96 in all electrophysiological measurements. 
Abbreviations. C5a-R, human C5a-receptor: fMLF, N-formyl- 
methionylleucylphenylalaline; fMLF-R, human fMLF-receptor: 
GPCR, G-protein-coupled receptor: hC5a, recombinant human CSa. 
2.2. Preparation of cRNA 
For all experiments with G~-I6, a subclone in the HindIII site of 
plasmid vector pCDM8 was used. cRNA for the human fMLF-R, 
0014-5793/95/$9.50 g 1995 Federation of European Biochemical Societies. All rights reserved. 
SSDI 0014-5793(95)01379-2 
M. Burg et aZ / FEBS Letters 377 (1995) 426 428 427 
C5a-R and G~-16 was prepared from the T7 promotor of the recombi- 
nant pCDM8 constructs after linearization with HpaI (fMLF-R and 
G~-16) or Xbal (C5a-R) using the mCAP mRNA capping kit (Strat- 
agene), cRNA was quantitated by densitometric evaluation from ethid- 
ium bromide stained agarose gels against aknown RNA standard using 
the CS-1 photographic system (Cybertech). 
U-937 cells were grown at 37°C in a humidified atmosphere with 5% 
CO2 in RPMI 1640 medium (Gibco) supplemented with 10% (w/v) 
heat-inactivated f tal calf serum, 50 U/ml penicillin and 50/lg/ml strep- 
tomycin. Total RNA was prepared by the guanidinium isothiocyanate 
method [19] and stored at -70°C in H_,O. 
2.3. Oocyte xpression experiments 
Preparation of defolliculated Xenopus laevis oocytes and electrophys- 
iological recordings were performed essentially as described previously 
[11,14,20]. RNA (46 nl/oocyte) was injected by a motor-driven microin- 
jector (Drummond) using glass capillaries broken to an outer diameter 
of 12~5 ,urn. For co-injection experiments equal amounts of each RNA 
were used. Two days later, the oocytes were voltage-clamped at -70 mV 
and functional receptor activity was measured by whole cell current 
recordings after exposure to ND96 containing 20 nM rhC5a or 1/tM 
fMLF, respectively, for 60 s. A response >5 nA was considered positive. 
3. Results and discussion 
In previous experiments we have demonstrated the absolute 
dependence of functional C5a-R expression in Xenopus laevis 
oocytes from one or several factors present in the total RNA 
fraction of the myelomonocytic U-937 cell line [14]. Similar 
results have been independently obtained by other researchers 
[15l. 
The recent description of G~-I6 as signalling pathway com- 
plementing factor for functional C5a-R expression in eukar- 
yotic cell lines [16,17] prompted us to test whether this G- 
protein was able to complement the signal transducing pathway 
in Xenopus oocytes, as well. As shown in Table 1, co-injection 
o fcRNA for G~-16 together with cRNA for the human C5a-R 
resulted in functional C5a-R expression. In comparison to com- 
plementation with total RNA of the U-937 cell line the signal 
intensity was considerably increased. Current amplitudes 
> 1000 nA were easily detected in the electrophysiological assay 
while the signal intensity with complementing RNA from U- 
937 cells rarely exceeded 100 nA (and was much smaller in most 
cases). The typical shape of the current response (If, s, followed 
by an extended I~low with a lower amplitude) was conserved. 
A similar dependence of functional receptor expression in 
Xenopus oocytes on co-injected complementing factor(s) pres- 
ent in the RNA of the myelomonocytic HL-60 cell line had been 
reported for the human fMLF-R [12,13]. We thus checked 
whether G~-16 would also complement fMLF-R activity in 
Xenopus oocytes. As shown in Table 2 and Fig. 1, expression 
of the fMLF-R alone led in contrast o the above-mentioned 
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Fig. 1. Whole cell currents of oocytes exposed to 1 pM fMLF for 60 s 
(horizontal bar). Oocytes were injected with 23 ng cRNA for the fMLF- 
R and 23 ng of cRNA for Ga-16 (top), 46 ng ofcRNA for the fMLF-R 
(middle) and 46 ng cRNA for Gc~-16 (bottom). 
reports - to some functional activity which in our hands could 
only marginally increased by co-injection ofU-937 RNA.  How- 
ever, co-injection of cRNA for G~-16 together with cRNA for 
the human fMLF-R  significantly increased the electrophysiol- 
ogical response. Thus, the human fMLF-R couples to Ga-16 
in Xenopus laevis, too. 
Very recently, it was reported that G~-16 may couple to a 
Table 1 
Summarized ata of the C5a-R expression experiments in Xenopus oocytes (with and without G~-16) 
n (series no.) Current response 
yes no 
Mean amplitude + S.D. 
(positive ggs) 
C5a-R cRNA plus U-937-RNA 
C5a-R cRNA plus Gc~-16 cRNA 
G(z-16 cRNA 
10 (1) 6 (60%) 4 (40%) 38 + 55 
7 (2) 4 (57%) 3 (43%) 16 - 14 
9 (I) 9 (100%t 0 (0%) 685 -+ 483 
11 (2) I0 (91%) 1 (9%) 345 +_ 377 
13 (1) 0 (0%) 13 (100%) 
10 (2) 0 (0%) 10 (100%) 
Injected oocytes were voltage-clamped at -70 mV and the ligand-induced current response was measured at day 3 post injectionem after superfusion 
with 20 nM rhC5a for 60 s. 
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Table 2 
Summarized ata of the fMLF-R expression experiments in Xenopus oocytes (with and without Gc~-I6) 
fMLF-R cRNA 
fMLF-R cRNA plus U-937-RNA 
fMLF-R cRNA plus G~-16 cRNA 
Gc~-I 6 cRNA 
n (series no.) Current response Mean amplitude + S.D. 
(positive ggs) 
yes no 
9 (1) 6 (67%) 3 7.5 -+ 6.1 
4 (3) 1 (25%) 3 30 
9 (1) 6 (67%) 3 (33%) 25 + 13 
8 (2) 3 (38%) 5 (63%) 8 +- 8.5 
3 (3) 3 (100%) 0 (0%) 11.5 + 7.5 
12(11 11 (92%) 1 (8%) 117+88 
8 (2) 8 (100%l 0 (0%) 116-+ 73 
6 (3) 6 (100%) 0 (0%) 59 + 22 
4 (4) 4 (100%) 0 (0%) 295 + 164 
5 (1) 0 (0%) 5 (100%) 
5 (2) 0 (0%) 5 (100%) 
5 (3) 0 (0%) 5 (100%) 
Injected oocytes were voltage-clamped at -7(I mV and the ligand-induced current response was measured at day 3 post-injectionem after superfusion 
with 1 ,uM fMLF for 60 s. 
wide variety of GPCR in eukaryotic ell lines [21]. This obser- 
vation does also apply to the Xenopus expression system, as 
shown by the data presented herein, and should allow for the 
establishment of a functional test system for virtually any 
GPCR in Xenopus laevis oocytes. The physiological significance 
of this rather unselective coupling of G~-16 to every GPCR 
tested so far remains unknown, as expression of this G-protein 
seems to be restricted to cells of hematopoietic origin [22]. But 
it is certainly expressed in the HL-60 [22] and U-937 cell lines 
[23] as shown by Northern hybridizations. These data clearly 
suggest hat Gc~-16 is the complementing factor previously de- 
scribed in these cell lines. The failure to detect this G-protein 
in U-937 cells by Vanek et al. [24] is probably simply due to 
differences in cell treatment or may indicate variant cell clones. 
In summary, we have shown that G:~-16 complements the 
signal transduction cascade of the human fMLF-R and C5a-R 
in Xenopus laevis oocytes and is most probably the comple- 
menting factor previously described in HL-60 and U-937 cells 
[12 15]. The signal intensity could be considerably increased as 
compared to our previous results obtained with co-injection of 
total RNA from these cell lines. Thus, injection of cRNA for 
G~-I6 considerably improves the sensitivity of the Xenopus 
laevis oocyte test system which now' recommends itself for the 
functional characterization of GPCR or appropriate receptor 
mutants, respectively, as we have recently demonstrated using 
some C5a-R mutants [25]. 
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